Niadyne Pharma is developing pharmaceutical indications for two dermatology conditions with high market potential, a first in class indication for prevention of
pre-cancerous actinic keratosis skin lesions and treatment of mild to moderate plaque psoriasis for patients where the risk and costs of treatment with biologics
is not warranted. NPI believes Nia-114's efficacy profile represents a new paradigm in dermatology such that it has the potential to be "a pipeline within
a drug" due to its ability to improve the skin barrier and normalize immune function in a wide range of dermatology diseases and conditions. Additional
potential of the technology for other conditions with impaired skin barrier integrity is also described.
